Drug Data Classification Mechanism of Action Indication Contraindications Adverse Reaction Nursing Responsibilities

Generic Name Pharmacologic General Indications Concentrations CNS: Restlessness, Before

Terbutaline Class In low doses, acts relatively - Prophylaxis and - Hypersensitivity to apprehension, anxiety, fear, - Observe 15 rights of drug
sulfate Beta2-selective selectively at beta2-adrenergic treatment of bronchial terbutaline CNS stimulation, hyperkinesia, administration.
adrenergic receptors to cause asthma and reversible - Tachyarrhythmias, insomnia, tremor, drowsiness, - Reduce dosage with hepatic or
Trade Name antagonist bronchodilation and relax the bronchospasm that tachycardia caused irritability, weakness, vertigo, renal failure.
Brethine pregnant uterus; may occur with by digitalis headache, seizures - Assess for hypersensitivity to drug.
Therapeutic At higher doses, beta2 bronchitis and intoxication - Assess for any contraindications to
Minimum Dose Class selectively is lost and the drug emphysema, in - General anesthesia CV: Cardiac arrhythmias, the drug.
5 mg at 6-hr Antasthmatic, acts at beta1 receptors to cause patients 12 yr and with halogenated palpitations, angina pain, - Educate about side effects of
intervals tid Bronchodilator, typical sympathomimetic older hydrocarbons or changes in BP and ECG drug.
Sympathomimetic cardiac effects. - Unlabeled use: cyclopropane
Maximum Dose , Tocolytic drug Tocolytic to prevent - Unstable vasomotor GI: Nausea, vomiting, During
15 mg/day Pharmacokinetics preterm labor system disorders heartburn, unusual or bad taste - Use minimal doses for minimal
Pregnancy Risk - Labor and delivery in mouth periods of time, drug tolerance
Contents Factor D: May cross placenta; enters - Lactation can occur with prolonged use.
Terbutaline B breast milk Respiratory: Respiratory - Keep a beta-blocker, such as
Precaution atenolol, readily available in
su M: Tissue difficulties, pulmonary edema,
- Diabetes, Coronary case cardiac dysrhythmias
lf E: Urine coughing, bronchospasm
insufficiency, CAD, occur.
at
History of CVA, COPD - For oral forms, administer with
e Rout Onset Peak Duratio Other: Sweating, pallor,
e n patient, water to facilitate swallowing.
flushing, muscle cramps,
Oral 30 2-3 hr 4-8 hr Hyperthyroidism, - For parenteral forms, avoid
Availability and elevated LFTs
min History of seizure contact with the needle.
color SubQ 5-15 30-60 1.5-4 hr disorder, - Stay with patient throughout
- Tablets: 2.5, 5 min min
Psychoneurotic
mg whole duration of
individuals, administration.
- Injection: 1 Drug Half Life
Hypertension
mg/mL 2-4 hr
After
Drug interaction - Monitor client for at least 30
Routes of > Drug to drug
administration minutes.
- Increased likelihood - Arrange for regular follow-up,
Oral of cardiac
Subcutaneous including blood tests, to
arrhythmias with evaluate effects.
halogenated - Instruct to report chest pain,
hydrocarbon dizziness, insomnia, weakness,
anesthetics tremor or irregular heartbeat,
- Risk of failure to respond to usual
bronchospasms if dosage.
combined with - Instruct to take medication as
diuretics directed for the full course of
- Increased risk of therapy, even if feeling better.
hypokalemia and - Do not double dose.
ECG changes with - Do proper documentation.
MAOIs and TCAs

> Drug to food

- none reported
Source: Source: Source: Source: Source: Source: Source:
Karch, Amy: 2009 Karch, Amy: 2009 Karch, Amy: 2009 Lippincott’s Nursing Karch, Amy: 2009 Lippincott’s Karch, Amy: 2009 Karch, Amy: 2009 Lippincott’s Nursing Karch, Amy: 2009 Lippincott’s Nursing
Lippincott’s Nursing Lippincott’s Nursing Drug Guide, pp. 1125-1126 Nursing Drug Guide, pp. 1126 Lippincott’s Nursing Drug Drug Guide, pp. 1126 Drug Guide, pp. 1127
Drug Guide, pp. 1125- Drug Guide, pp. 1125 Guide, pp. 1126
1126